Veron Lucie, Wehrer Delphine, Caron Olivier, Balleyguier Corinne, Delaloge Suzette
Institut Gustave-Roussy, département d'oncologie médicale, programme interception (prévention personnalisée des cancers), Villejuif, France.
Institut Gustave-Roussy, département d'oncologie médicale, service d'oncogénétique, Villejuif, France.
Bull Cancer. 2022 Jul-Aug;109(7-8):786-794. doi: 10.1016/j.bulcan.2022.02.006. Epub 2022 May 5.
French breast cancer screening is based on organized screening with a mammography every two years for women between 50 and 74, and individualized screening for women at high or very high risk of breast cancer (personal history of breast cancer or atypical breast lesion or thoracic radiotherapy before the age of 25, high family risk without genetic mutation, genetic mutation). A novel approach of risk-based breast cancer screening is currently under evaluation in many countries, including France. This personalized screening, based on individual risk of having breast cancer in the next years, uses algorithms which combine clinical parameters, mammographic density, familial history and genomic (using polygenic risk score), to estimate breast cancer risk and adapt screening's frequency.